Collaboration Agreement Sample Contracts

Magenta Therapeutics, Inc. – BE THE MATCH BIOTHERAPIES(r) COLLABORATION AGREEMENT (May 24th, 2018)

This Collaboration Agreement (including all attachments hereto, this Agreement) is entered into and made effective November 10, 2017, by and between Be The Match BioTherapies (BTMB), a Minnesota nonprofit corporation, having its headquarters at 500 North 5th Street, Minneapolis, MN 55401, and Magenta Therapeutics, Inc., a Delaware corporation (Magenta), having a principal place of business at 50 Hampshire St, Cambridge, MA 02139 (each a Party and collectively the Parties).

AMENDMENT No. 2 TO THE COLLABORATION AGREEMENT (May 4th, 2018)

THIS AMENDMENT NO. 2 TO THE COLLABORATION AGREEMENT (this "Collaboration Amendment" or this "Agreement"), entered into as of January 6, 2018 (the "Execution Date"), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware ("Alnylam") and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts ("Genzyme").

Marika – License & Collaboration Agreement by and Between Pieris Pharmacueticals Inc., Pieris Pharmaceuticals Gmbh & Pieris Australia Pty. Limited and Astrazeneca Ab (April 26th, 2018)
AMENDMENT No. 1 to the Collaboration Agreement Between Novartis Pharma AG and Amgen Inc. (April 25th, 2018)

This Amendment No. 1 ("Amendment") is entered into as of March 20, 2018 ("Amendment No. 1 Effective Date") by and between Novartis Pharma AG, a Swiss corporation having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland ("Novartis"), and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA ("Amgen"). Novartis and Amgen are each referred to individually as a "Party" and together as the "Parties".

American Funeral Svcs Corp – Collaboration Agreement (April 17th, 2018)

COLLABORATION AGREEMENT (the "Agreement"), dated as of April 9, 2018, between Rokk3r Inc., a Nevada corporation ("ROKK"), and Rokk3r Labs LLC., a Florida company ("R3L"), such entities being sometimes referred to herein individually as the "Party" and together as the "Parties."

Cosmos Group Holdings Inc. – Car Rental Collaboration Agreement (April 17th, 2018)

Address: Shop No. 105-109, 1/F & Shop No. 201-208, 210-218, 2/F, No.38 Guihe Road, Shuitou Road Section, Huaya Plaza, Nanhai Qu, Foshan City, Guangdong Province, China

Collaboration Agreement JAGUAR HEALTH INC. And SEED MENA BUSINESSMEN SERVICES L.L.C. 17th Floor, Burjuman Business Center P. +971 4 325 2444 [email protected] Bur Dubai, United Arab Emirates F. +971 4 3858 333 www.seedgroup.com (April 9th, 2018)

SEED MENA BUSINESSMEN SERVICES L.L.C, a corporation organized and existing in accordance with the laws of Dubai, United Arab Emirates, and having its principal place of business at Burjuman Business Tower, Dubai, United Arab Emirates, hereafter referred to as SEED or the First Party (which expression shall unless excluded by or repugnant to the context be deemed to include its successors-in-title, authorized representatives, administrators and permitted assigns) and represented in this Agreement by its Chief Executive Officer, Mr. Hisham Al Gurg, UAE National and holder of Passport No: A2555704; of the First Party

Magenta Therapeutics, Inc. – BE THE MATCH BIOTHERAPIES(r) COLLABORATION AGREEMENT (March 28th, 2018)

This Collaboration Agreement (including all attachments hereto, this Agreement) is entered into and made effective November 10, 2017, by and between Be The Match BioTherapies (BTMB), a Minnesota nonprofit corporation, having its headquarters at 500 North 5th Street, Minneapolis, MN 55401, and Magenta Therapeutics, Inc., a Delaware corporation (Magenta), having a principal place of business at 50 Hampshire St, Cambridge, MA 02139 (each a Party and collectively the Parties).

Surface Oncology, Inc. – COLLABORATION AGREEMENT by and Between SURFACE ONCOLOGY, INC. And NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. (March 23rd, 2018)

THIS COLLABORATION AGREEMENT (this Agreement), entered into as of January 9, 2016 (the Effective Date), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (Surface), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (Novartis). Surface and Novartis are referred to in this Agreement individually as a Party and collectively as the Parties.

Denali Therapeutics Inc. – OPTION AND COLLABORATION AGREEMENT Between DENALI THERAPEUTICS INC. And TAKEDA PHARMACEUTICAL COMPANY LIMITED (March 19th, 2018)

This Option and Collaboration Agreement (the Agreement) is made and entered into effective as of January 3, 2018 (the Execution Date) by and between Denali Therapeutics, Inc., a Delaware corporation (Denali), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (Takeda). Denali and Takeda are sometimes referred to herein individually as a Party and collectively as the Parties.

Surface Oncology, Inc. – COLLABORATION AGREEMENT by and Between SURFACE ONCOLOGY, INC. And NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. (March 5th, 2018)

THIS COLLABORATION AGREEMENT (this Agreement), entered into as of January 9, 2016 (the Effective Date), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (Surface), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (Novartis). Surface and Novartis are referred to in this Agreement individually as a Party and collectively as the Parties.

Unum Therapeutics, Inc. – [***] Indicates Material That Has Been Omitted and for Which Confidential Treatment Has Been Requested. All Such Omitted Material Has Been Filed With the Securities and Exchange Commission Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended Collaboration Agreement by and Between Unum Therapeutics, Inc. And Seattle Genetics, Inc. Dated as of June 7, 2015 (March 2nd, 2018)

THIS COLLABORATION AGREEMENT (the Agreement) is entered into as of June 7, 2015 (the Effective Date) by and between UNUM THERAPEUTICS, INC., a Delaware corporation having its principal place of business at One Broadway 4th Floor, Cambridge, MA 02142 (Unum), and SEATTLE GENETICS, INC., a Delaware corporation having a principal office at 21823 30th Drive SE, Bothell, WA 98021 (SGI). Unum and SGI are sometimes referred to herein individually as a Party and collectively as the Parties.

Intrexon Corp – Second Amendment to Exclusive Channel Collaboration Agreement (March 1st, 2018)

This SECOND AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the "Amendment") is effective as of November 8, 2017 (the "Second Amendment Effective Date") by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 ("Intrexon") and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. ("Oragenics"). Intrexon on the one hand and Oragenics on the other hand may be referred to herein individually as a "Party", and collectively as the "Parties."

Intrexon Corp – First Amendment to Exclusive Channel Collaboration Agreement (March 1st, 2018)

THIS FIRST AMENDMENT (the "Amendment") is entered into as of this 21stday of July, 2016 and serves to amend the Exclusive Channel Collaboration Agreement entered into by and between Intrexon Corporation ("Intrexon") and Oragenics, Inc. ("Oragenics") on June 5, 2012 (the "Agreement"). All capitalized terms not defined herein shall have the meaning set forth in the Agreement.

Orthofix International N.V. – Amendment No. 6 to Matrix Commercialization Collaboration Agreement (February 26th, 2018)

THIS AMENDMENT NO. 6 TO MATRIX COMMERCIALIZATION COLLABORATION AGREEMENT (this "Amendment No. 6") is dated as of December 29, 2017 (the "Amendment No. 6 Effective Date") by and between Musculoskeletal Transplant Foundation, Inc., a non-profit corporation formed under the laws of the District of Columbia, and having a principal place of business at 125 May Street, Suite 300, Edison, New Jersey 08837 ("MTF"), and Orthofix Holdings, Inc., a corporation organized under the laws of the State of Delaware, and having a principal place of business at 3451 Plano Parkway, Lewisville, Texas 75056 ("Orthofix") (each individually a "Party" and collectively the "Parties").

Unum Therapeutics, Inc. – [***] Indicates Material That Has Been Omitted and for Which Confidential Treatment Has Been Requested. All Such Omitted Material Has Been Filed With the Securities and Exchange Commission Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended Collaboration Agreement by and Between Unum Therapeutics, Inc. And Seattle Genetics, Inc. Dated as of June 7, 2015 (February 13th, 2018)

THIS COLLABORATION AGREEMENT (the Agreement) is entered into as of June 7, 2015 (the Effective Date) by and between UNUM THERAPEUTICS, INC., a Delaware corporation having its principal place of business at One Broadway 4th Floor, Cambridge, MA 02142 (Unum), and SEATTLE GENETICS, INC., a Delaware corporation having a principal office at 21823 30th Drive SE, Bothell, WA 98021 (SGI). Unum and SGI are sometimes referred to herein individually as a Party and collectively as the Parties.

Copytele – Note: Confidential Treatment Requested With Respect to Certain Portions Hereof Denoted With [***] COLLABORATION AGREEMENT (January 9th, 2018)

THIS AGREEMENT is entered into on November 17, 2017 (hereinafter Effective Date) by and between H. Lee Moffitt Cancer Center and Research Institute, Inc. a non-profit Florida corporation organized pursuant to Section 1004.43, Florida Statutes, whose address is 12902 Magnolia Drive Tampa, Florida 33612 (Moffitt) and Certainty Therapeutics, Inc., a corporation duly organized under the laws of Delaware whose address is 3150 Almaden Expressway, Suite 250, San Jose, California 95118 (hereinafter "Company"). Moffitt and Company are hereinafter referred to individually as Party and collectively as Parties.

Surface Oncology, Inc. – COLLABORATION AGREEMENT by and Between SURFACE ONCOLOGY, INC. And NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. (November 17th, 2017)

THIS COLLABORATION AGREEMENT (this Agreement), entered into as of January 9, 2016 (the Effective Date), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (Surface), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (Novartis). Surface and Novartis are referred to in this Agreement individually as a Party and collectively as the Parties.

Nuvelo – Amendment to European Addendum to the Clinical Trial Collaboration Agreement Between Medtronic and Arca (November 9th, 2017)

This Amendment, effective July 10, 2017, amends the European Addendum to the Clinical Trial Collaboration Agreement between Medtronic, Inc. ("Medtronic") and ARCA biopharma, Inc. ("ARCA"), which became effective September 14, 2016 ("Agreement").

Oragenics, Inc. – Second Amendment to Exclusive Channel Collaboration Agreement (November 9th, 2017)

This SECOND AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the Amendment) is effective as of November 8, 2017 (the Amendment Effective Date) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (Intrexon), INTREXON ACTOBIOTICS NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no. 0882.251.820 (Ghent), Belgium (Actobiotics), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (Oragenics). Intrexon and Actobiotics together on the one hand and Oragenics on the other hand may be referred to herein individually as a Party, and collectively as the Parties.

Oragenics, Inc. – Second Amendment to Exclusive Channel Collaboration Agreement (November 9th, 2017)

This SECOND AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the Amendment) is effective as of November 8, 2017 (the Second Amendment Effective Date) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (Intrexon) and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (Oragenics). Intrexon on the one hand and Oragenics on the other hand may be referred to herein individually as a Party, and collectively as the Parties.

Collaboration Agreement (November 8th, 2017)

This COLLABORATION AGREEMENT (this "Agreement") is made and entered into as of August 4, 2017 (the "Effective Date"), by and between NanoString Technologies, Inc., a Delaware corporation located at 530 Fairview Avenue, N., Suite 2000, Seattle, Washington 98109, ("NanoString"), and Lam Research Corporation, a Delaware corporation located at 4650 Cushing Parkway, Fremont, CA 94538 ("Lam"). NanoString and Lam are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Arsanis, Inc. – Collaboration Agreement (October 20th, 2017)

THIS COLLABORATION AGREEMENT (the Agreement) is made as of the date the later- signing party signs this Agreement (Signing Date), to have effect retroactive to May 1, 2011 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 16 Cavendish Court, Lebanon, NH 03766 (Adimab) and ARSANIS, INC., a Delaware corporation having an address at 16 Cavendish Court, Lebanon, NH 03766 (together with Arsanis Biosciences GmbH, an Austrian entity having an address at Helmut-Qualtinger-Gasse 2, Vienna, A-1030, Austria, collectively Arsanis).

SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT BY AND BETWEEN PSIVIDA US, INC. (F/K/a CONTROL DELIVERY SYSTEMS, INC.) AND ALIMERA SCIENCES, INC. DATED AS OF JULY 10, 2017 (September 13th, 2017)
XRpro Sciences, Inc. – SECOND Amendment to ASSET PURCHASE AND COLLABORATION AGREEMENT (August 16th, 2017)

This Second Amendment (this "Amendment"), dated as of August 14, 2017 and effective as of May 31, 2017 (the "Effective Date"), to the Asset Purchase and Collaboration Agreement, dated as of June 26, 2015 and amended on July 13, 2016 (the "Original Agreement"), by and between Pfizer Research (NC), Inc. (f/k/a Icagen, Inc.), a Delaware corporation ("Pfizer" or the "Seller"), and Icagen Inc. (f/k/a XRpro Sciences, Inc.), a Delaware corporation ("Icagen" or the "Buyer").

Marika – License & Collaboration Agreement by and Between Pieris Pharmacueticals Inc., Pieris Pharmaceuticals Gmbh & Pieris Australia Pty. Limited and Astrazeneca Ab (August 11th, 2017)

This License and Collaboration Agreement (the Agreement), entered into as of May 2, 2017 (the Execution Date) by and between Pieris Pharmaceutical, Inc. (Pieris US), a corporation existing under the laws of the State of Nevada having a principal place of business at 255 State Street, 9th Floor, Boston, MA 02109, Pieris Pharmaceuticals GmbH (Pieris Germany), a company existing under the laws of Germany having a principal place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany, Pieris Australia Pty. Ltd. (Pieris Australia), a company existing under the laws of Australia with its registered address at Level 8, 123 Pitt Street, Sydney NSW 2000, Australia (Pieris US, Pieris Germany, and Pieris Australia are collectively referred to as Pieris) and AstraZeneca AB, a corporation existing under the laws of Sweden having a principal place of business at S-431 83 Molndal, Sweden (AstraZeneca). Pieris and AstraZeneca are referred to in this Agreement individually as a Party and colle

2017 Amendment to Amended and Restated Collaboration Agreement (August 10th, 2017)

This 2017 Amendment to the Amended and Restated Collaboration Agreement (the "Amendment") by and between Alimera Sciences, Inc. ("Alimera") and pSivida US, Inc. (f/k/a pSivida, Inc., "pSivida," and with Alimera, the "Parties") is effective this 3rd day of May 2017 (the "Effective Date").

Arsanis, Inc. – Collaboration Agreement (August 10th, 2017)

THIS COLLABORATION AGREEMENT (the Agreement) is made as of the date the later- signing party signs this Agreement (Signing Date), to have effect retroactive to May 1, 2011 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 16 Cavendish Court, Lebanon, NH 03766 (Adimab) and ARSANIS, INC., a Delaware corporation having an address at 16 Cavendish Court, Lebanon, NH 03766 (together with Arsanis Biosciences GmbH, an Austrian entity having an address at Helmut-Qualtinger-Gasse 2, Vienna, A-1030, Austria, collectively Arsanis).

Third Amendment to the Collaboration Agreement (August 2nd, 2017)

This third amendment (the "Amendment") to the Collaboration Agreement dated December 22, 2006, as amended, (the "Agreement") between Exelixis, Inc. ("Exelixis") and Genentech, Inc. ("Genentech") is made and entered into by Exelixis and Genentech effective July 19, 2017 (the*"Amendment Effective Date"). All capitalized terms not expressly defined in this Amendment shall have the meaning assigned to them in the Agreement.

Collaboration Agreement by and Between Amgen Inc. And Novartis Pharma Ag Dated April 21, 2017 (July 26th, 2017)

This Collaboration Agreement (this "Agreement"), effective as of April 21, 2017 (the "Effective Date"), is by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. ("Amgen"), and Novartis Pharma AG, a Swiss company having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland ("Novartis"). Amgen and Novartis are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Rich Pharmaceuticals, Inc. – Support and Collaboration Agreement (July 12th, 2017)

This Support and Collaboration Agreement (the "Agreement") is effective as of July 11, 2017 ("Effective Date") by and between Rich Pharmaceuticals, Inc., a Nevada corporation ("Rich"), and Mega Bridge, Inc., a Nevada corporation, to be renamed "Hypgen" ("Hypgen").

Asset Solutions Inc – Support and Collaboration Agreement (July 12th, 2017)

This Support and Collaboration Agreement (the "Agreement") is effective as of July 11, 2017 ("Effective Date") by and between Rich Pharmaceuticals, Inc., a Nevada corporation ("Rich"), and Mega Bridge, Inc., a Nevada corporation, to be renamed "Hypgen" ("Hypgen").

Mersana Therapeutics, Inc. – CONFIDENTIAL AMENDMENT NUMBER ONE to the COLLABORATION AGREEMENT (June 1st, 2017)

THIS AMENDMENT NUMBER ONE (this Amendment), dated June 17, 2014, is by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab) and MERSANA THERAPEUTICS, INC., a Delaware corporation having an address at 840 Memorial Drive, Cambridge, MA 02139 (Mersana), and this Amendment amends the Collaboration Agreement (the Agreement) dated July 25, 2012, by and between Adimab and Mersana. Capitalized terms used herein and not defined shall have the meanings ascribed to such terms in the Agreement.

Mersana Therapeutics, Inc. – AMENDMENT NUMBER ONE to the COLLABORATION AGREEMENT (June 1st, 2017)

This AMENDMENT NUMBER ONE (this Amendment), dated February 21, 2013, amends the COLLABORATION AGREEMENT (the Agreement) is made as of July 25, 2012 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab) and MERSANA THERAPEUTICS, INC., a Delaware corporation having an address at 840 Memorial Drive, Cambridge, MA 02139 (Mersana).

Mersana Therapeutics, Inc. – Confidential Collaboration Agreement by and Between Adimab, Llc and Mersana Therapeutics, Inc. July 25, 2012 (June 1st, 2017)

THIS COLLABORATION AGREEMENT (the Agreement) is made as of July 25, 2012 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab) and MERSANA THERAPEUTICS, INc., a Delaware corporation having an address at 840 Memorial Drive, Cambridge, MA 02139 (Mersana).